

v1: 2 April 2025

Review Article

Gestational Inflammation: Its Foetal Control and the Proper Therapeutic Approach

Peer-approved: 2 April 2025

© The Author(s) 2025. This is an Open Access article under the CC BY 4.0 license.

Qeios, Vol. 7 (2025)
ISSN: 2632-3834

Fortunato Vesce¹

1. University of Ferrara, Italy

Inflammation triggers coagulation. Gestational inflammation, with its vascular implications, is the cause of major obstetric complications, from sporadic and recurrent miscarriage to foetal growth restriction, premature delivery with all its nefarious perinatal sequels, up to the most dramatic scenarios of foetal and maternal death: it is neither adequately diagnosed nor promptly and exhaustively counteracted by current obstetrics. Controlling gestational inflammation in normal pregnancy is primarily a foetus's job. The vast majority of aneuploid fetuses are unable to control normal gestational inflammation and are therefore spontaneously aborted. Euploid fetuses may be unable to control normal gestational inflammation, and in this case, they are aborted or suffer from the inflammatory complications of advanced pregnancy. This article reports a selection of the best scientific evidence on gestational inflammation. It also analyses the current therapeutic approach, with particular regard to the use of glucocorticoids throughout pregnancy.

Correspondence: papers@team.qeios.com — Qeios will forward to the authors

Premise

It is worth considering in advance that pregnancy is made possible thanks to an invasion of the maternal endometrium by the trophoblast surrounding the blastocyst. Such invasion generates a cellular reaction^[1], the nature of which is primarily of an inflammatory type. It belongs to the cellular branch of the immune response, leaving the humoral one perfectly operative.

A favorable outcome is only possible if the trophoblast is able to turn off the inflammatory endometrial reaction it itself has caused. This means that physiological pregnancy is largely under foetal control. Foetuses (i.e., trophoblast) unable to properly modulate the local maternal reaction sign their own death warrant.

The physiological role of the 'inflammatory mediators'

The normal evolution of pregnancy is the result of deep vascular changes in the maternal organism under the control of foetal mediators. According to their prevalent action, a taxonomic classification can divide these mediators into inflammatory and anti-inflammatory. However, they are known to play either role, depending on the cell type and the circumstances of their involvement, in response to the activation of the actors of the opposite function. Indeed, the so-called 'inflammatory' ones primarily regulate physiological functions, such as ovulation, menstruation, labor, and many others. In search of scientific evidence of the physiologic role of such mediators, the receptor ligands for the inflammatory peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) were found to be present in amniotic fluid. Their concentration increases with labor, while fMLP receptors are expressed in amnion

tissue^{[2][3][4][5]}. So, what are these inflammatory mediators for? Can normal labor be considered an inflammatory process? Not entirely. Certainly, it often presents with pain, heat, and functional impairment, like it may happen during menstruation: and to some extent, labor can be considered a delayed menstruation, as Gustavii pointed out a long time ago^[6].

Is fMLP involved in the control of menstruation as well? After all, understanding the physiological role of these mediators is not a simple matter of measurement. fMLP is only one among many chemotactic factors able to modulate cytokines, including IL-1 alpha and IL-1 beta gene expression and IL-6 secretion, which in turn are known to modulate inflammation^[7].

Therefore, it should be interesting to explore the behavior of the peptide in the genesis of premature labor and foetal systemic inflammation, a syndrome preceded by an increase in IL6 concentration in the foetal compartment. However, even if that were the case, it would be a drop in the ocean! A large network of gestational cytokines, chemokines, peptides, and prostanoids has been investigated in both experimental and clinical conditions, with sometimes controversial results. Nevertheless, over the course of half a century, the inflammatory nature of the major complications of pregnancy has been widely recognized at least on a pathological level, if not on a clinical one.

In this article, the concept of gestational inflammation will be discussed in its broadest sense, from the natural maternal immune response to its physiological control by the foetus, up to its harmful pathological deviations. Furthermore, the therapeutic approach will be analyzed with particular attention to the balance of the mediators that trigger inflammation, thus paving the way for infection, and to the use of glucocorticoids for the prevention of pregnancy loss.

A look at the nature and mechanism of gestational inflammation

Between the two endpoints of conception and delivery, the process of placentation takes place, during which the maternal and foetal immune systems interact with each other. This occurs through the release of specific mediators of opposite function, the maternal ones being more addressed towards inflammation, whereas the foetal ones act against it. The earliest stage of the foetal-maternal competition occurs at the beginning of blastocyst implantation in the uterine mucosa. Mainstream clinicians are accustomed to considering such an early stage separately from advanced

pregnancy, when the foetus is now capable of extrauterine life. Nevertheless, both from a biological and clinical point of view, the functional evolution of the trophoblast must be considered a unitary and continuous process until delivery. Indeed, the same inflammatory deviation of its function that triggers miscarriage later can lead to premature birth, chorioamnionitis, nefarious perinatal complications, up to the loss of both the foetus and the mother.

During the three-day travel from the tube to the uterine cavity, the product of conception does not need to come into contact with the maternal blood, since everything it needs is already in its baggage. Later, when the trophoblast cells reach the mucosa, they differentiate into two types, respectively called extra-villous and villous. The first type is responsible for structural and functional changes in the maternal vessels^[5]. It penetrates the uterine arterioles and disrupts their wall, causing the leakage of blood in which the chorionic villi are immersed to drain increasing quantities of nutrients and oxygen.

As in any other vascular district of the body, this generates an inflammatory reaction, aimed at reducing blood leakage by means of vasoconstriction and coagulation. The activation of such a natural response would appear to hinder the ultimate goal of a normal birth, but in physiological pregnancy, this is not the case. In fact, the foetal immune system takes over the maternal one to preserve optimal placental perfusion until childbirth. In its competition with the maternal immune system, foetal self-defense is essentially accomplished by counteracting vasoconstriction and blood coagulation. For this purpose, extravillous trophoblast cells progressively eliminate the smooth muscle from the wall of the spiral artery up to its myometrial tract. The consequent vasodilatory effect produces a continuous, low-resistance blood flow. At the same time, coagulation is prevented by replacing the endothelial lining of the vascular intima with trophoblastic cells. In this way, the local maternal platelet activation does not take place, and thrombosis is not triggered.

These structural changes of the uterine arterioles were clearly described by Harold Fox in his classic text entitled 'Pathology of the Placenta'^[8].

At the same time, the trophoblastic cells directly produce functional mediators^[5], and stimulate the release of many others by maternal platelets, as well as by immune and other cells. Therefore, it is right to state that pregnancy is directly under the control of the foetus itself: *foetus faber fortunae suae!*

On the other hand, contrary to some unproven opinions, the maternal immunity against infectious diseases remains fully operative throughout pregnancy. The idea of an assumptive “fragility” of the pregnant woman is completely devoid of any scientific basis. It derives solely from the hypothesis that the foetus should be ‘rejected’, because the mother’s immune system does not recognize its paternal genetic component. According to this opinion, maternal tolerance would be accomplished through a reduction of the humoral immunity, thus leading to an increased risk of infection. A corollary of this unproven risk should be the need to resort to vaccines, whose number is continuously increasing, and whose efficacy and safety have never been reliably investigated. Instead, contrary to the opinion of an increased risk of serious infections accredited by the World Health Organization, the admission rate to the Intensive Care Unit is significantly lower for pregnant women. Moreover, no increased need for ventilatory support, nor a greater likelihood of severe outcomes and maternal death compared to either the general population or non-pregnant women of reproductive age, is reported. Only a higher rate of hospitalization is registered, rightly ascribed to better care for motherhood^[9].

Surprisingly, however, the above data have been interpreted in the opposite meaning by others^[10]. To give greater credence to an increased risk of maternal death, these authors go back to the 1918 flu pandemic, an era when the therapeutic efficacy of antibiotics, anticoagulants, and anti-inflammatory drugs was unknown!

Unfortunately, however, vaccination, by definition, entails inflammation, thus strengthening the normal maternal cellular immune reaction^[11], with a consequent increased risk of foetal demise. It is the author’s opinion that, given the current uncertainties, it may be best to exercise caution regarding vaccinations during pregnancy until more research is available.

Foetal-maternal regulation of immune and vascular function

Many of the pregnancy-related mediators of the cellular functions are secreted by two subpopulations of lymphocytes (Th1 and Th2) derived from the functionally undiscriminated type (Th0). The Th1-type produces mainly interleukins (IL-1, IL-2, IL-12, IL-15, IL-18), interferon gamma (IFN- γ), and tumor necrosis factor-alpha (TNF- α), known to mediate cellular immunity. Th2 produces IL-4, IL-5, IL-6, IL-10, IL-13,

and granulocyte-macrophage colony-stimulating factor (GM-CSF), which control the humoral response^{[12][13]}. Moreover, Th2 cytokines prevent Th1 cytokine secretion^[14].

The pro-inflammatory/anti-inflammatory cytokine ratio is enhanced in preeclampsia. It is probably associated with an excessive production of inflammatory agents, among which IL-12^[15]. Placental ischemia, consequent to poor spiral artery remodeling^[16], enhanced Th1/Th2 ratio^[17] and pro-angiogenic/anti-angiogenic factor imbalance^[18] may promote inflammatory changes through the release of Th-1 cytokines and ROS with consequent endothelial dysfunction, leading to the release of humoral factors responsible for the clinical symptoms of preeclampsia^[19].

As for the gestational evolution of cytokine balance, based on circulating levels of interferon-gamma (IFN-gamma) and interleukin-6 (IL-6) as Th1 and Th2 biomarkers respectively, the variation of their ratio was investigated in the maternal blood of 35 women from 10 to 40 weeks of pregnancy. It is important to note that IFN-gamma levels decrease with gestational age, whereas those of IL-6 increase. The IFN-gamma/IL-6 ratio switches around the 19th week of pregnancy. Therefore, the Authors suggest that the Th1 bias may be prevailing at the beginning of pregnancy, balanced in the middle, and supplanted by the Th2 bias at the end^[20].

These results should be taken into account when the cytokines are tested for statistical or diagnostic purposes.

Many other factors are involved in the differentiation and specialization of trophoblastic cells from implantation to delivery. During early pregnancy, low oxygen is reported to prevent trophoblast differentiation towards an invasive phenotype. Low oxygen effects are mediated by hypoxia-inducible factor-1 (HIF-1alpha subunit), whose expression parallels that of transforming growth factor-beta3 (TGFbeta3), an inhibitor of early trophoblast differentiation^{[21][22]}.

Abnormalities in TGF- β 3 expression are associated with preeclampsia, and it has been demonstrated that down-regulation of this growth factor restores the invasive capability of preeclamptic trophoblast cells^[23].

A crucial role for optimal fetal oxygenation and growth is exerted by prostacyclin (PGI₂), a prostanoid with vasodilatory and anticoagulant functions. It is produced

by both the mother and the fetus for the entire duration of pregnancy. Placental cells in culture synthesize and release PGI₂. Its production appears to increase with gestational age, so that preterm and term placental PGI₂ production is significantly greater than that in the first trimester.

Notably, the synthesis of PGI₂ is inhibited by the cyclooxygenase inhibitors indomethacin and aspirin, a potentially dangerous effect, considering the wide clinical use of these drugs^[24].

Indeed, as patients with recurrent miscarriage have significantly increased platelet aggregation in response to arachidonic acid, the use of aspirin in the management of this condition is suggested^[25]. Therefore, aspirin is expected to hinder thromboxane on the one hand, thus counteracting the formation of the platelet thrombus, but also to inhibit prostacyclin production on the other, in this way promoting vasoconstriction and thrombosis. Indeed, the action of prostacyclin is normally counterbalanced by thromboxane (TxA₂), a prostanoid responsible for vasoconstriction and thrombosis, which is released by various cells, among which endothelial, macrophages, and neutrophils. The enhancement of thromboxane release is the natural consequence of inflammation. The maternal inflammatory response is not limited to platelet activation, but widely affects other tissues, among which is the endothelial lining of uterine arteries. Women whose pregnancies end in abortion have a higher output of 2,3-dinor-TxB₂ (a thromboxane metabolite) and lower excretion of 2,3-dinor-6-keto-PGF_{1α} (a prostacyclin metabolite), with a lower ratio of prostacyclin to thromboxane, indicating a thromboxane dominance and prostacyclin deficiency compared with women whose pregnancies proceed to term^[26].

These data underline the importance of a balanced prostacyclin/thromboxane ratio in pregnancy.

In apparent contrast with the evidence that increased platelet aggregation is a cause of severe complications, among which increased miscarriage rate, pre-eclampsia, and pregnancy loss, reduced platelet aggregation in response to adenosine diphosphate and thrombin receptor activating peptide was reported in patients with a history of recurrent miscarriage in comparison with those of the same group who subsequently had successful pregnancies. Women with subsequent miscarriages also have a trend towards reduced platelet aggregation in response to epinephrine^[27].

However, it must be considered that in vivo platelet dysfunction is a complex process that cannot be simply reduced to more or less experimental in vitro aggregation.

Further questions regarding platelet dysfunction concern the complexity of the maternal inflammatory response and the adequacy of the adopted therapy. As it will be seen later, the ability of aspirin to inhibit thromboxane formation in vitro does not provide any significant clinical advantage in terms of live birth rate and fetal well-being.

Potential causes of enhanced gestational inflammation

Once the prevalent inflammatory nature of major obstetric complications is understood, its prevailing causes must be carefully considered. In this regard, the current attitude is to look for maternal infectious, immune, and genetic causes.

As for the first, the stubborn search for potential pathogens appears to be no longer necessary, since the foetus's inability to turn off the maternal immune reaction - unleashed by himself - is sufficient to explain even the most serious consequences. After all, free mother-to-child transmission of viruses and their specific antibodies has been reported in normal pregnancy^{[28][29]}. Moreover, HPV infection is rare in chorionic villi and is not related to abortion^[30]. As for *Ureaplasma parvum* and *urealyticum*, *Mycoplasma genitalium* and *hominis*, and *Chlamydia trachomatis*, their DNA sequences are found with similar frequency in peripheral blood mononuclear cells of spontaneous and voluntary aborters^[31]. On the other hand, it is logical to believe that the mere presence of viruses and bacteria is not a sufficient cause of disease, because it is known that healthy carriers do exist. The independence of the onset of inflammation from pathogens is indirectly demonstrated in the above-mentioned 'syndrome of the systemic foetal inflammatory response' (Romero - Gomez Syndrome)^[32]. In this condition, high levels of foetal IL6 are found in the foetal compartment before the onset of premature birth symptoms, suggesting the existence of a foetal cytokine imbalance preceding the eventual infection. Nevertheless, the widely held belief that inflammation is triggered by infection is claimed on the basis of the curative effect of antibiotics. However, it has been shown that, in the absence of infection, Ampicillin is able to inhibit amniotic Prostaglandin E and IL6 release, in this way directly counteracting inflammation^{[33][34]}.

Furthermore, it is reported that Ceftriaxone and Gentamicin exert the same action, although to a lesser extent. On the contrary, Tetracycline and Erythromycin do not influence the prostanoïd output. The inhibitory (i.e., anti-inflammatory) effect of Ampicillin is potentiated in an additive manner by Ceftriaxone, reduced by Gentamicin, and eliminated by Tetracycline and Erythromycin^[35].

These data should open a serious debate on the current interpretation of healing from antibiotics: is it the result of their direct anti-inflammatory action rather than the antibacterial one? Or: to what extent is it the result of both?

Autoimmune syndromes and diseases of the maternal connective tissue are a well-known cause of recurrent miscarriage. Nevertheless, successful pregnancy is possible, although at the cost of an increased risk of complications^[36].

The foetal-maternal genetic control of gestational inflammation

A large number of maternal and foetal cells produce immune mediators, but a clear assessment of their role in the genesis of different gestational situations has not yet been sufficiently clarified. While the role of the maternal immune system is beyond question, its control by the foetus still awaits to be adequately understood. Indeed, there is much evidence to suggest that the foetus itself governs the balance of gestational immunity. The above-mentioned Romero-Gomez Syndrome, for example, indicates that the foetal inflammatory state may not be triggered by infection. Accordingly, it has also been postulated that successful pregnancy induces an immune bias towards Th2 immunity, and a Th2 cytokine imbalance is believed to cause intrauterine growth restriction and foetal death. Further evidence points to a foetal role in triggering increased or unbalanced release of pro-inflammatory mediators. Indeed, maternal peripheral mononuclear cells stimulated with trophoblast antigens from growth-restricted fetuses produce higher levels of pro-inflammatory cytokines compared with normally grown fetuses^{[37][38][39]}.

Growth restriction, therefore, can be considered a consequence of low utero-placental perfusion caused by vasoconstriction and thrombosis of uterine spiral arterioles, i.e., by the normal maternal inflammatory response, which growth-restricted fetuses lack the ability to switch off. This foetal idiopathic inability may well be one cause of the shift towards Th1-type

immunity^[39] which is a reported cause of 'unexplained' pregnancy failure.

Once the foetus' inability to properly control the maternal inflammatory reaction has been recognized, we must find out where it originates from. To answer this question, the mediators of inflammation, coagulation, and vascular function released by aneuploid fetuses were investigated, in order to verify whether an increased or unbalanced output could justify their high abortion rate.

A raised amniotic fluid level of endothelin, a potent vasoconstrictor, was found in the presence of aneuploidy compared to normal pregnancies^[40]. Moreover, abnormality of the plasminogen activation system was reported in aneuploid pregnancies, possibly leading to impaired utero-placental perfusion, thus to abortion, foetal growth restriction, and death^[41]. Accordingly, the amniotic fluid of Down Syndrome pregnancies displays increased TGF-beta activity and lacks IL-2 immunoactivity^[42]. Moreover, down-regulation of adhesion molecules such as integrin- α , and upregulation of MMP-9 are reported in trisomy 21, with possible impairment in trophoblast function. These alterations may be responsible for the increase in cytotrophoblast apoptosis^[43]. Further amniotic fluid abnormalities in aneuploid pregnancies are an increase of interleukin-6 ($P = 0.034$) and a decrease of interleukin-8 ($P < \text{or} = 0.0001$)^[44].

In addition, the receptors of adenosine, a pro-angiogenic nucleoside, were investigated in 71 first-trimester chorionic villi samples and cultured mesenchymal cells from euploid and trisomy 21 pregnancies. Overall, the adenosine transduction cascade appears to be disturbed in Trisomy 21 through reduced expression of A_{2B} and A_{1A} receptors^[45].

All these anomalies of mediators of inflammation, coagulation, and vascular function are causes of foetal growth restriction, malformation, and death, thus leading to the high rate of aneuploid pregnancy loss.

If the above-reported evidence speaks in favor of a foetal genetic cause for the lack of proper control of immune and vascular function in the presence of aneuploidy, what can be said for euploidy?

Progress in genetic polymorphism research answers this question. Genetic polymorphism means that the structure or nucleotide arrangement of the same gene may vary between individuals. The variations are compatible with life and may affect numerous genes,

including those associated with angiogenesis, thrombogenesis, and immune response^[46].

Maternal common inflammatory polymorphisms entail an increased risk of recurrent miscarriage and preterm birth^{[47][48]}. Consistent with the increased risk of preterm birth that inflammatory polymorphisms entail, a decreased risk is reported for the anti-inflammatory ones^[49].

Furthermore, maternal polymorphisms of the immunoregulatory genes IL10, MBL2, TNFRSF6, and TGFβ1 influence the susceptibility to chorioamnionitis and other unfavorable pregnancy outcomes^[50].

While maternal polymorphisms are widely studied, the same cannot be said for the foetal ones. This reflects the current and often erroneous opinion that adverse pregnancy events are attributable to maternal pathological conditions. On the contrary, since both the maternal and foetal immune systems modulate the utero-placental function, foetal genetic polymorphisms have the same importance as maternal ones in determining the fate of the pregnancy.

Clinical implications of the foetal-maternal immune system mutual modulation

The evidence reported above is only a small part of the large amount of data in the scientific literature on cytokine modulation in pregnancy. As mentioned in the introduction, the maternal inflammatory response is not in itself a pathological event, as long as the foetus is able to counteract it. It turns into pathology only when the spatial-temporal production of inflammatory cytokines is uncontrolled, and the Th1 foetal-maternal immune response takes over the Th2 one^[51].

So, slowly, the idea of counteracting inflammation has made its way into the minds of obstetricians. It must be said, however, that the maternal immune reaction to trophoblast invasion is not currently seen as a possible cause of miscarriage. According to mainstream obstetrics, the most accredited causes are maternal diseases, including connective tissue chronic inflammation, thrombophilia, and infection. Indeed, an increased risk of miscarriage and other complications is registered in the presence of such pathologic conditions. Nevertheless, physiological pregnancy, albeit less frequently, can occur in these patients, thus confirming the opinion that a better genetic polymorphism of the new foetus may be able to control the maternal immune system.

Ignoring the possible role of gestational inflammation in the genesis of obstetrical complications, current obstetrics does not effectively counteract it. Therapy is still basically anchored to weak measures dating back to the first half of the last century: robust doses of progesterone, weak doses of aspirin, and in some cases, ineffective glucocorticoids.

Progesterone

Progestagens are prescribed routinely for the protection of early and late pregnancy. Initially, the reason for their use was the maintenance of electrical and mechanical quiescence of the myometrium. As for their utility, the need for progesterone action on the endometrium for implantation is known and beyond question. It is worthwhile to recall that around the end of last century, a combination of hydroxiprogesterone caproate plus estradiol valerate was approved for the cure of threatened miscarriage^[52] as well as for osteopenia due to hypogonadism^{[53][54]}, for stimulation of breast enlargement^[55] and also for contraception^[56]. However, so far, there is no clinical evidence of real efficacy in protecting pregnancy against severe inflammatory complications. Only in 2007 was the *estro-progestin* combination withdrawn from the Italian market. Nevertheless, new potential indications for progesterone administration are produced by tireless scientific research, among which is a possible anti-inflammatory action that should make its use suitable against miscarriage^[57]. Fortunately, however, the real usefulness of progestogens in the prevention of obstetric complications is slowly coming out. According to FIGO Good Practice Recommendations^[58], evidence on the use of progesterone for the prevention of recurrent miscarriage demonstrates no significant difference in live birth rates compared to placebo. Similarly, a recent meta-analysis of seven randomised trials involving 5,682 women concluded that progestogens probably make little or no difference to the live birth rate for women with threatened or recurrent miscarriage^[59]. Furthermore, the method of pessary administration of 400 mg vaginal progesterone for threatened miscarriage does not increase the live birth rate^[60]. Although other authors seem to interpret the recommendations of the guidelines in a more reassuring way^[61], a further meta-analysis confirmed that progestogens probably make little or no difference to the live birth rate for women with threatened or recurrent miscarriage^[62].

It should seem instead that vaginal micronized progesterone may increase the live birth rate for women with a history of one or more previous miscarriages and early pregnancy bleeding; thus, progesterone shows inconsistent behavior in relation to the administration route. However, as regards the efficacy limited to cases with early bleeding, one possible explanation could be that some of them may not be true cases of threatened abortion: the blood may come from the decidua parietalis. Indeed, it is known that in early pregnancy, the gestational sac does not occupy the entire uterine cavity, and there are women who may experience mild bleeding during the period of missed menstruation until late in the second trimester: this has little or nothing to do with threatened miscarriage. Strictly speaking, bleeding should be considered a sign of threatened abortion only when it is caused by the disruption of the normal relationship between chorionic villi and uterine spiral arterioles. In a previous randomized multicenter trial in which 400 mg of vaginal progesterone was given twice daily to patients with a history of recurrent miscarriage from a positive pregnancy test until 12 weeks, there was no significant difference in live birth after 24 weeks compared to placebo^[63]. Nevertheless, the National Institute for Health and Care Excellence (NICE) recommends offering vaginal micronised progesterone 400 mg twice daily until 16 completed weeks to pregnant women with vaginal bleeding and a history of one previous miscarriage. Actually, a single miscarriage can be due to causes that do not benefit from progesterone, such as occasional aneuploidy. Moreover, the duration of the therapy is questioned. It has been highlighted that the increase in live birth rate at 34 weeks is only 3%; it is registered only in women with 3 previous miscarriages, and the beneficial effect occurs at 9 weeks' gestation, i.e., at the time of the shift in progesterone production from the corpus luteum to the placenta. This suggests that there is no need for hormone supplementation until the 16th week. The need to investigate the long-term effects of progesterone on brain development has also been highlighted^[64].

The American College of Obstetrics and Gynecology Clinical Guidance for the prevention of recurrent premature birth by progesterone supplementation was recently updated. Quoting Conde-Agudelo and Romero^[65], the Committee states that vaginal progesterone may be prescribed to women with a history of preterm birth, a singleton pregnancy, and a shortened cervix. On the contrary, prevention of recurrent preterm birth between 20 and 37 weeks of gestation with intramuscular administration of 17-OHP

is not supported by the current body of evidence, and therefore it is not approved by the FDA^[66]. In this regard, the American College Committee notes that the FDA decision does not appear to be based on "safety concerns", and "does not provide any basis for evaluating potential progesterone efficacy in a subset of the general population": in other words, it seems that the Committee wants to distance itself from the FDA's position. However, the Committee does not seem at all surprised by the difference in efficacy of progesterone, which appears to be mild via the vaginal route but is completely absent via the systemic route. It is not easy to figure out the reason for the intramuscular route failure, considering the prompt hematogenous spread to all organs and tissues, including the vagina. Finally, one would expect that, by inhibiting myometrial contraction, progesterone administered before cervical shortening would be more effective than after the process has already begun. In addition, the concern of the American Committee for the apparent indifference of the FDA as regards safety and potential efficacy on population subsets seems to be misplaced, because it may be relevant to research, but not yet to clinical care. How can these incongruities be explained? It would seem that proven clinical efficacy is still an essential condition for authorizing the administration of a drug to the human population.

Further attempts to support the mild action of progesterone have been made by combining the therapy with cerclage. However, the hormone is supposed to counteract the increased myometrial contractility triggered by gestational inflammation, while the surgical tightening of the cervix can only be effective in the absence of inflammatory myometrial contractions. Therefore, an eventually increased efficacy of this combined approach requires that patients with two different pathogenic mechanisms are mixed in the study population. Nevertheless, a trial speaks in favor of an increased efficacy of combined progesterone and cerclage in singleton gestation compared to each of the two single therapies^{[67][68]}. On the contrary, a meta-analysis evaluating both the vaginal and intramuscular routes of progesterone combined with cerclage and pessary in twin pregnancies with short cervical length reported no reduction of preterm birth < 34 weeks of gestation^[69].

Overall, the efficacy of progesterone in the management of miscarriage, premature birth, pregnancy loss, and related complications appears to be uncertain or weak, and does not justify its widespread and indiscriminate prescription.

Aspirin

The pathogenic link between inflammation and thrombosis, and their role in obstetric complications, guided some clinical preventive strategies. As mentioned above, thromboxane A2 is released from platelets, macrophages, neutrophils, trophoblast, and endothelial cells as a consequence of tissue injury and inflammation. In addition, it is also reported to augment cellular immune responses and inflammatory tissue injury^[70]. Vasoconstriction and platelet aggregation caused by the prevalent action of thromboxane are attenuated by aspirin, whose inhibitory action is supposed not to extend to prostacyclin. Therefore, based on the known deficiency in prostacyclin and overproduction of thromboxane A2 in women with a history of recurrent miscarriage, 50 mg of aspirin was daily given throughout pregnancy to 66 patients. The therapy was able to decrease thromboxane A2 production without influencing prostacyclin concentration, but no improvement in live birth rate was observed^[71]. Low-dose aspirin was also recommended for the prevention and treatment of preeclampsia because the disease is characterized by an imbalance of the thromboxane/prostacyclin ratio, due to increased thromboxane production.

On the other hand, attempts to treat preeclampsia by direct prostacyclin administration yielded poor results^[72].

However, current evidence does not support low-dose aspirin for the prevention of miscarriage, fetal growth restriction, stillbirth, and preterm birth^[73].

As regards the mild effectiveness of aspirin, it must be considered that gestational inflammation cannot be reduced to the simple increase of thromboxane: it involves a series of mediators of cellular immunity that may be insensitive to the COX2 inhibitory action of aspirin; it is logical to assume that a higher degree of inflammation requires a stronger protection. It was therefore thought that this could somehow be obtained by combining aspirin with heparin.

Heparin

Ten years ago, a meta-analysis evaluated nine studies that included 1228 women with a history of recurrent miscarriage, with or without inherited thrombophilia, treated with aspirin and/or heparin: no beneficial effect of the anticoagulant in studies at low risk of bias was found^[74]. Soon after, thromboprophylaxis with 4000 IU/day low molecular weight heparin was tested in a prospective observational study on 150 women with a

history of two or more first-trimester miscarriages. Contrary to the result of the previous meta-analysis, live birth was achieved in 85%, compared to 66% in the untreated control group^[75]. Moreover, an increase in live birth rate has been reported by combining aspirin plus heparin in women with persistent antiphospholipid antibodies^[76]. On the contrary, in a more recent international open-label, randomised controlled trial, low molecular weight heparin administered to women who had two or more pregnancy losses and confirmed inherited thrombophilia did not result in higher live birth rates^[77].

Glucocorticoids (GC)

Cortisone was used in 1953 to treat hyperemesis gravidarum. Twenty-nine women were given doses of 25 to 75 mg/day for 5 to 64 days, with complete remission of the symptoms within 36 hours, without any negative effect on the neonates^[78]. Today, glucocorticoid prescription is widespread during mid- and late pregnancy, while little is known about its potential significance in early pregnancy. Stimulation of HCG secretion, suppression of uterine Natural killer cells, and promotion of trophoblast growth/invasion have been reported among the positive effects, while the negatives could be inhibition of cytokine-prostaglandin signalling, restriction of trophoblast invasion following up-regulation of plasminogen activation inhibitor-1, induction of apoptosis, and inhibition of embryonic and placental growth^[79].

The clinical rationale for the use of GC in the management of the major obstetric complications is simple: since all of them have an inflammatory pathogenesis, all of them may benefit from the complex anti-inflammatory action of these hormones. It could be argued that the other drugs mentioned above also exert a direct or indirect anti-inflammatory action, but their effectiveness is very limited. GCs, instead, are known to control the mediators of cellular functions, among which are IL-1, IL-6, IL-8, Tumor necrosis factor, Granulocyte-macrophage Colony-stimulating factor, and Monocyte chemotactic protein-1 factor^[80]. Their action is exerted also on cellular cytokine receptors, which are increased in some cell types and decreased in others^[81]. Other examples of the regulatory actions of GCs are the down-regulation of the expression of the cellular receptors that recognise a variety of pathogens, named Toll-like receptors^[82], as well as the suppression of pro-inflammatory and up-regulation of anti-

inflammatory cytokines^[83]. Moreover, betamethasone reverses the migration dysfunction induced by arginine-vasopressin in HTR8/Svneo trophoblastic cells by reverting the matrix metalloproteinase-9-associated inflammation. Therefore, since arginine-vasopressin secretion is elevated throughout gestation in pregnancies complicated by pre-eclampsia, the use of betamethasone has been suggested as a novel therapeutic strategy for this syndrome^[84]. The above-mentioned effects on cells, cytokines, and receptors are indicative of the vast control that GCs exert on body functions. Nevertheless, despite the logical and experimental premises of their anti-inflammatory effectiveness, they are rarely used in pregnancy with this specific purpose. Even when they clearly do exert it, the result of their application is interpreted differently. For example, the betamethasone life-saving prevention and cure of neonatal hyaline membrane disease of the lung is currently all attributed to little-known maturational processes. Actually, the hormone directly stimulates lecithin release from the human foetal membranes, with a greater amnion response^[85]. This complex action, recently confirmed in the rabbit lung, appears to be mediated by a molecular mechanism that causes a decrease of Forkhead box M1, a protein involved in lung development^[86]. However, a large part of the ominous perinatal complications of premature neonates that benefit from betamethasone, including respiratory distress, encephalopathy, and necrotizing enterocolitis, is a direct consequence of inflammation rather than prematurity. Therefore, one should wonder to what extent the life-saving effect of betamethasone is attributable to the stimulated maturation as opposed to its powerful anti-inflammatory action.

Part of the caution in prescribing GC is due to the fear of adverse embryo-foetal malformative or maturation events, some of which have been produced experimentally in laboratory animals. As a consequence, there is a widespread tendency to avoid prescribing in early pregnancy or to resort to poorly effective types of these hormones. It is also believed that prednisolone does not reach the foetus and, therefore, cannot cause adverse effects on it. This is a questionable belief, since steroids are fat-soluble and therefore freely cross the cell membranes. Accordingly, placental 11 β -HSD2 has been shown to metabolise beclomethasone, prednisolone, dexamethasone, and betamethasone^[87]. Despite the above-mentioned prejudices, the use of GC, including fluorinated ones, is the mainstay for a variety of maternal and foetal pathologic conditions. Absolute indications are Addison's syndrome and hypopituitarism. Furthermore,

they are largely used in pregnant women with asthma, collagen disease, ulcerative colitis, regional enteritis, and those needing immunosuppression. The most frequent foetal indications for their use are reported below.

Foetal atrio-ventricular block

Isolated foetal complete atrio-ventricular block (AVB) is a condition that occurs in 1 of every 20,000 pregnancies. It results from lupus erythematosus, due to the transplacental passage of maternal anti-Ro/SSA and/or anti-La/SSB antibodies. However, other rheumatic diseases, among which Sjogren syndrome may be involved, and even foetuses of asymptomatic women can be affected.

Complete AVB usually develops during gestational weeks 16 to 24, with a 15 to 30% foetal mortality rate, and two-thirds of affected offspring requiring permanent pacing. The condition is associated with endocardial fibroelastosis and possible late-onset cardiomyopathy^[88]. Fluorinated GCs such as dexamethasone or betamethasone, given to the mother before 16 weeks' gestation, can prevent progression to third-degree AVB, alleviate cardiomyopathy^[89], and reduce the risk of developing antibody-mediated congenital heart block in the offspring^[90]. Moreover, by means of a foetal kinetocardiogram, it has been shown that fluorinated steroids normalize atrioventricular conduction in first-degree AVB^[91]. However, not all the above effects are confirmed, although there is agreement on the decreased risk of subsequent cardiomyopathy^[91]. Adverse effects on the foetal central nervous system, lung, retina, and adrenal glands have been ascribed to fluorinated corticosteroid administration. However, since they are associated with premature or very low-birth-weight newborns, the poor outcome can hardly be ascribed to GCs; rather, it should be accepted that, without treatment, those foetuses would never survive. Moreover, neurodevelopmental problems appear to be associated with postnatal rather than antenatal dexamethasone therapy. To avoid fluorinated steroids in women who previously had children with AVB or a skin rash, intravenous immunoglobulin is suggested. In these patients, serial echocardiograms are needed to detect premature atrial contractions or moderate pericardial effusion, which might be a target of preventive steroidal therapy^[92]. It is believed that in the presence of alarming symptoms, betamethasone is safer than dexamethasone^[93].

A recent study evaluated long-term outcomes after antenatal betamethasone therapy for AVB prevention. The body weight and height of the fourteen children enrolled were within the normal range, all had normal intelligence, and none had autism^[94].

Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia is caused by the loss or decreased activity of the enzymes involved in cortisol biosynthesis. In the vast majority of cases, 21-hydroxylase deficiency is found due to mutations in the gene CYP21A2, located on the short arm of chromosome 6^{[95][96]}. Congenital adrenal hyperplasia is a cause of physical and psychological virilization in affected females. Prenatal diagnosis is needed in pregnancies at risk, followed by GC administration in the positive cases. Chorionic villus sampling has been preferred because it can be performed at the 10th -12th week of gestation, much earlier than amniocentesis. A significant improvement is represented today by the noninvasive diagnosis using cell-free DNA in maternal plasma^[97].

Dexamethasone administration to the pregnant mother is effective in reducing genital virilization. Data from large human studies show that dexamethasone administered even before 10 weeks of gestation does not induce significant or enduring side effects, neither in the mother nor in the foetus, and the newborns do not differ in weight, length, or head circumference from untreated unaffected newborns^[98].

Cystic adenomatoid malformation of the lung

Cystic adenomatoid malformations of the foetal lung (CCAM) are rare embryonic developmental abnormalities characterized by overgrowth of the terminal respiratory bronchioles at the expense of the saccular spaces. Although rare cases of spontaneous resolution are reported, CCAM are generally coupled with a high incidence of foetal or neonatal death. Several cases are reported about the efficacy of betamethasone in the management of CCAM complicated by fetal hydrops. The standard dose of 12 mg, twice 24 hours apart, for the prevention of hyaline membrane disease leads to the complete resolution of the condition. In a clinical study on eleven patients, survival was 100% in foetuses with hydrops or a CCAM, and resolution of hydrops was seen in 80% of steroid-treated patients^[99]. In some cases, however, despite the therapy and the resolution of hydrops, late intrauterine death occurred, suggesting that the malformation may

have a preeminent role in the final outcome^[100]. While negative clinical effects of betamethasone are not reported in these patients, it seems that the clinical assessment of this pathologic condition requires a deeper clinical assessment^[101].

Alloimmune Thrombocytopenia

Alloimmune thrombocytopenia is analogous to the foetal/neonatal anaemia caused by haemolytic disease of the foetus and newborn. Foetal antigens, which are normally expressed on platelets from the 16th week of pregnancy, may cause maternal immunisation, so that foetal and placental transfer of IgG antibodies may lead to neonatal thrombocytopenia. It has been reported that there is an increase in the fetal platelet count after maternal treatment with prednisone (10 mg/daily) from 23 weeks' gestation^[102]. Alloimmune thrombocytopenia is cured today by intravenous immune globulin administered by 24 weeks' gestation to pregnant women at risk due to a previously affected infant. Immunoglobulin 1 g/kg weekly with or without oral dexamethasone was first reported to lower the incidence of foetal cerebral hemorrhage, increasing platelet count, compared to untreated patients. Dexamethasone 3-5 mg/d augments the effect of immune globulin, although, in some patients, it was associated with oligohydramnios and foetal growth restriction. Prednisone can also be used to treat foetuses with an inadequate response to immune globulin alone, but presumably because of its lower anti-inflammatory action, a dose of 60 mg/daily is required. Overall, weekly immune globulin 1 g/kg starting at 24 weeks' gestation is the mainstay of therapy, while adjunctive corticosteroids are suggested in women who have failed prior treatments^[103].

Recurrent Pregnancy Loss

Despite the caution commonly recommended in the use of glucocorticoids during pregnancy, their efficacy and substantial harmlessness have been reported several times, even in the prevention of pregnancy loss^[104]. As for maternal conditions that benefit from cortisone therapy, in addition to chronic inflammatory diseases with an autoimmune character, a significant improvement in knowledge came from studies on the role of uterine natural killer cell (uNK) cytotoxicity in recurrent miscarriage. In early pregnancy, there is an increase in uNK cells under the influence of steroids. They are believed to promote trophoblast growth and immune modulation at the foetal-maternal interface. Nevertheless, despite their presumptive physiological

role, uterine and peripheral NK cells are involved in recurrent miscarriage and pregnancy loss, and their toxicity participates in the rejection of the product of conception^[105]. GCs are able to suppress in vitro NK and other inflammatory cells' cytolytic activity and their tumor necrosis factor- α production^[106]. It is worth analyzing the case of a patient with a history of 19 consecutive miscarriages, in whom a high number of uNK cells had been found. She was first observed following 14 miscarriages between the 8th and the 10th gestational week. The remote medical history and the following investigation screen were negative: hormone profile, viral screen (toxoplasmosis, cytomegalovirus, hepatitis, and herpes simplex virus), autoimmune screen (anti-DNA, mitochondrial, and thyroid antibodies), full blood count, random blood sugar, karyotype analysis of both parents, ultrasound scan of the uterus, hysteroscopy, antiphospholipid syndrome screen including IgG and IgM anticardiolipin antibody titres and dilute Russell viper venom time, Leiden factor V gene mutation, prothrombin gene mutation, methyltetrahydrofolate reductase mutation, antithrombin III deficiency, and activated protein C resistance. The mid-luteal level of uNK was the highest the author had ever recorded. Pre-conceptual prednisolone 5 mg/daily was prescribed, leading to five further early losses. Therefore, a dose of 20 mg/daily preconceptional prednisolone was prescribed for 6 months prior to conception. The hormone administration was stopped at the 5th week of her twentieth gestation. The pregnancy was complicated by foetal growth restriction and oligohydramnios. A caesarean section was performed at 33 weeks, with the birth of a 1484 g female in good condition^[107]. This was an unexplained result in the opinion of the authors, although it is largely justified by the intensive regulatory action of the glucocorticoids on cellular and humoral immunity. In the absence of other maternal causes of miscarriage, the above-mentioned foetal inability to turn off maternal gestational inflammation may be considered a possible cause of the recurrent miscarriages in this patient. Moreover, the foetal growth restriction shows that, despite the high dose administered, the hormone was not able to completely remove the utero-placental vascular compromise produced by gestational inflammation. It has been suggested that estrogens and GCs could act directly on uNK cells through their receptors, influencing gene transcription at the decidual level. In addition, they downregulate inflammatory cytokine production by a variety of other cells^[108]. Although immunoglobulins are reported to be almost equally effective as

prednisolone in suppressing in vitro NK cell cytolytic activity, it must be recalled that GC immunomodulation is the result of a specific and complex action involving different cellular types and a large number of cytokines and prostanoids.

A combination of prednisone, aspirin, folate, and progesterone has been reported to be associated with a higher live birth rate and a better foetal outcome compared with no treatment^[109]. On the other hand, it has also been reported that elevated plasma cortisol concentration in early pregnancy may predict the subsequent risk of pre-term labour, with an apparent mediatory role for increased placental CRH output^[110]. Nevertheless, the eventual clinical relevance of this finding remains to be established. However, NK percentage and cytotoxicity are not the only features of gestational inflammation, since Th1/Th2 ratio imbalance is enough to trigger it. It follows that the measurement of this ratio in the maternal and foetal compartments is essential for the early diagnosis of potentially fatal complications.

Low-dose betamethasone alone throughout pregnancy for the prevention of gestational early and late inflammatory complications has been reported in patients with a history of recurrent miscarriage^{[111][112][113]}. According to the Authors, this therapy, named 'Irpinia Resolution', showed greater efficacy in terms of live birth rate and neonatal well-being compared to other treatments. The patients in their clinical studies, due to a history of 2 to 10 previous miscarriages or pregnancy losses, had already been studied with laboratory tests and operative hysteroscopies for the search of endometrial inflammatory cells, and treated with surgical excision of uterine fibroids or endometriosis foci. In addition, they had been treated with variable doses of single or combined drugs, including progesterone, aspirin, heparin, and prednisolone. Therefore, they were assigned to low-dose betamethasone therapy without further investigation and regardless of the results of previous tests. In the opinion of the Authors, there are three main reasons for the better performance of low-dose betamethasone (usually 0.5 mg/daily until delivery): first, the well-known greater anti-inflammatory activity of fluorinated GC compared to prednisolone; second, their resistance to inactivation by 11- β -hydroxysteroid-dehydrogenase; third, their broad action against all aspects of the complex process of cellular and humoral inflammation. Thanks to these characteristics, betamethasone exerts its action precisely where it is required, that is at the level of the

chorionic villi and maternal decidua, where gestational inflammation is triggered and produces its first effects.

Based on this evidence, these Authors encourage clinicians to adopt the 'Irpina Resolution' for the prevention of gestational inflammation in single cases, without fear of foetal and maternal adverse events. Once the potential of this therapy has been sufficiently confirmed in selected cases, further validation by means of case-control trials comparing treated with non-treated patients would be welcome before directing it to the general population.

Concluding remarks

Uncontrolled gestational inflammation is the cause of the major obstetric complications, including euploid and aneuploid sporadic and recurrent miscarriage, foetal growth restriction, premature birth, up to perinatal and maternal death.

Recognizing that major obstetric complications are due to the failure of the foetus to control gestational inflammation is not a common mental attitude among clinicians. It is the Author's opinion that a greater diagnostic effort on the foetal causes, and more effective anti-inflammatory steroid therapy, would significantly improve live birth rates and perinatal well-being, meeting the expectations of the women who suffer from the recurrent denial of their motherhood.

References

1. ^ΔJones RL, Stoikos C, Findlay JK, Salamonsen LA. TGF-β superfamily expression and actions in the endometrium and placenta. *Reproduction*. 2006; 132: 217–232.
2. ^ΔBiondi C, Pavan B, Dalpiaz A, Valerio A, Spisani S, Vesce F. Evidence for the presence of N-formyl-methionyl-leucyl-phenylalanine (fMLP) receptor ligands in human amniotic fluid and fMLP receptor modulation by physiological labour. *J Reprod Immunol*. 2005; 68:71–83.
3. ^ΔBiondi C, Pavan B, Ferretti ME, Corradini FG, Neri LM, Vesce F. Formyl-methionyl-leucyl-phenylalanine induces prostaglandin E2 release from human amnion-derived WISH cells by phospholipase C-mediated [Ca²⁺]i rise. *Biol Reprod*. 2001; 64:865–70.
4. ^ΔBuzzi M, Vesce F, Ferretti ME, Fabbri E, Biondi C. Does formyl-methionyl-leucyl-phenylalanine exert a physiological role in labor in women? *Biol Reprod*. 1999; 60:1211–6.
5. ^Δ^b Lunghi L, Ferretti ME, Medici S, Biondi C, Vesce F. Control of human trophoblast function. *Reprod Biol Endocrinol*. 2007 Feb 8; 5:6.
6. ^ΔLabour: a delayed menstruation? Bjorn Gustavii. *Lancet*. vol 300, issue 778, 1149–1150 Nov 25, 1972. doi:10.1016/s0140-6736(72)92759-6
7. ^ΔN Arbour, P Tremblay, D Oth N. formyl – methionyl – leucil – phenylalanine induces and modulates IL-1 and IL-6 in human PBMC. *Cytokine*. 1996 Jun; 8(6):468–75. doi:10.1006/cyto.1996.0063
8. ^ΔHarold Fox 'Pathology of the Placenta' (ISBN 13:9780702021961).
9. ^ΔMertz D, Geraci J, Winkup J, Gessner BD, Ortiz JR, Loeb M. Pregnancy as a risk factor for severe outcomes from influenza virus infection: a systematic review and meta-analysis of observational studies. *Vaccine*. 2017; 35:521–8.
10. ^ΔCornish EF, Filipovic I, Asenius F, Williams DJ, McDonnell T. Innate Immune Responses to Acute Viral Infection During Pregnancy. *Front Immunol*. 2020; 11: 572567.
11. ^ΔFortunato Vesce, Chiara Battisti, Michele Crudo. The Inflammatory Cytokine Imbalance for Miscarriage, Pregnancy Loss and COVID-19 Pneumonia. *Front Immunol*, 11 March 2022; 13 – 2022. doi:10.3389/fimmu.2022.861245
12. ^ΔWilczynski JR. Th1/Th2 cytokines balance – yin and yang of reproductive immunology. *Eur J Obstet Gynecol Reprod Biol*. 2005; 122: 136–143.
13. ^ΔBelardelli F. Role of interferons and other cytokines in the regulation of the immune response. *Apmis Journal of Pathology, microbiology and Immunology*. 1995; 103: 161–179.
14. ^ΔDarmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, Oleszczuk J. T helper 1- and t helper 2-type cytokine imbalance in pregnant women with pre-eclampsia. *Eur J Obstet Gynecol Reprod Biol*. 1999; 86: 165–170.
15. ^ΔSaito S, Sakai M. Th1/Th2 balance in preeclampsia. *J Reprod Immunol*. 2003; 59: 161–173. doi:10.1016/S0165-0378(03)00045-7
16. ^ΔKharfi A, Giguère Y, Sapin V, Massé J, Dastugue B, Forest JC. Trophoblastic remodeling in normal and preeclamptic pregnancies: implication of cytokines. *Clin Biochem*. 2003; 36: 323–331. doi:10.1016/S0009-9120(03)00060-2
17. ^ΔYoneyama Y, Suzuki S, Sawa R, Yoneyama K, Power GG, Arami T. Relation between adenosine and T-helper 1/T-helper 2 imbalance in women with preeclampsia. *Obstet Gynaecol*. 2002; 99: 641–646. doi:10.1016/S0029-7844(02)01657-5
18. ^ΔKoga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia.

- ia. *J Clin Endocrinol Metab.* 2003; 88: 2348-2351. doi:10.1210/jc.2002-021942
19. [△]Lala PK, Chakraborty C. Factors regulating trophoblast migration and invasiveness: possible derangements contributing to pre-eclampsia and fetal injury. *Placenta.* 2003; 24: 575-587. doi:10.1016/S0143-4004(03)00063-8
20. [△]Aziz Aris, Frédéric Lambert, Paul Bessette, Jean-Marie Moutquin. Maternal circulating interferon- γ and interleukin-6 as biomarkers of Th1/Th2 immune status throughout pregnancy. *The Journal of Obstetrics and Gynaecology Research.* 01 November 2007. doi:10.1111/j.1447-0756.2007.00676.x
21. [△]I Caniggia, J Winter, S J Lye, M Post. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. *Placenta.* 2000 Mar-Apr;21 Suppl A:S25-30. doi:10.1053/plac.1999
22. [△]I Caniggia, J L Winter. Adriana and Luisa Castellucci Award lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and pre-eclamptic pregnancies--a review. *Placenta.* 2002 Apr;23 Suppl A:S47-57. doi:10.1053/plac.2002.0815
23. [△]Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, Post M, Lye SJ. Inhibition of TGF- β 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. *J Clin Invest.* 1999; 103: 1641-1650.
24. [△]M. Jogee, L. Myatt, P. Moore, M.G. Elder. Prostacyclin production by human placental cells in short-term culture. *Placenta.* Volume 4, Issue 3, July-September 1983, Pages 219-229. doi:10.1016/S0143-4004(83)80001-0
25. [△]Flood K, Peace A, Kent E, Tedesco T, Dicker P, Geary M, Malone FD, Kenny D. Platelet reactivity and pregnancy loss. *Am J Obstet Gynecol.* 2010 Sep;203(3):281.e1-5. doi:10.1016/j.ajog.2010.06.023. Epub 2010 Aug 3. PMID: 20684942
26. [△]M. Tulppala MD, Prof O. Ylikorkala MD, L. Viinikka M D. Thromboxane dominance and prostacyclin deficiency in habitual abortion. *The Lancet.* Volume 337, Issue 8746, 13 April 1991, Pages 879-881. doi:10.1016/0140-6736(91)90205-4
27. [△]Mark Anthony Dempsey, Karen Flood, Naomi Burke, Aoife Murray, Brian Cotter, Sieglinde Mullers, Patrick Dicker, Patricia Fletcher, Michael Geary, Dermot Kenny, Fergal D Malone. Platelet function in patients with a history of unexplained recurrent miscarriage who subsequently miscarry again. *Eur J Obstet Gynecol Reprod Biol.* 2015 May;188:61-5. doi:10.1016/j.ejogrb.2015.02.003. Epub 2015 Feb 26.
28. [△]Mazzoni E, Di Stefano M, Fiore JR, Destro F, Manfrini M, Rotondo JC, Casali MV, Vesce F, Greco P, Scutiero G, Martini F, Tognon MG. Serum IgG Antibodies from Pregnant Women Reacting to Mimotopes of Simian Virus 40 Large T Antigen, the Viral Oncoprotein. *Front Immunol.* 2017 Apr 10;8:411. doi:10.3389/fimmu.2017.00411. eCollection 2017.
29. [△]Elisa Mazzoni, Elena Pellegrinelli, Chiara Mazziotta, Carmen Lanzillotti, John Charles Rotondo, Ilaria Bononi, Maria Rosa Iaquina, Marco Manfrini, Fortunato Vesce, Mauro Tognon, Fernanda Martini. Mother-to-child transmission of oncogenic polyomaviruses BKPyV, JCpV and SV40. *J Infect.* 2020 May;80(5):563-570. doi:10.1016/j.jinf.2020.02.006. Epub 2020 Feb 22.
30. [△]Tognon M, Tagliapietra A, Magagnoli F, Mazziotta C, Oton-Gonzales L, Lanzillotti C, Vesce F, Contini C, Rotondo J C, Martini F. Investigation on spontaneous abortion and Papilloma Virus infection. *Vaccines.* 2020;8(3):47.
31. [△]Contini C, Rotondo JC, Magagnoli F, Maritati M, Seraceni S, Graziano A, Poggi A, Capucci C, Vesce F, Tognon M, Martini F. Investigation on silent bacterial infection in specimens from pregnant women affected by spontaneous miscarriage. *Journal of Cellular Physiology.* 2018; 234(1):100-107. doi:10.1002/jcp.26952.
32. [△]Romero R, Gomez R, Ghezzi F, Yoon BH, Mazor M, Edwin SS, Berry SM. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. *Am J Obstet Gynecol.* 1998 Jul;179(1):186-93. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. *Am J Obstet Gynecol.* 1998 Jul;179(1):194-202.
33. [△]Vesce F, Buzzi M, Ferretti ME, Pavan B, Bianciotto A, Iorizzo G, Biondi C. Inhibition of amniotic prostaglandin E release by ampicillin. *Am J Obstet Gynecol.* 1998 Apr;178(4):759-64.
34. [△]Vesce F, Pavan B, Lunghi L, Giovannini G, Scapoli C, Piffanelli A, Biondi C. Inhibition of amniotic interleukin-6 and prostaglandin E2 release by ampicillin. *Obstet Gynecol.* 2004 Jan;103(1):108-13.
35. [△]Vesce F, Pavan B, Buzzi M, Pareschi MC, Bianciotto A, Iorizzo G, Biondi C. Effect of different classes of antibiotics on amniotic prostaglandin E release. *Prostaglandins Other Lipid Mediat.* 1999 Jun;57(4):207-18.
36. [△]Merz WM, Fischer-Betz R, Hellwig K, Lamprecht G. Pregnancy and autoimmune disease. *Deutsch Arztebl Int.* 2022; 119(9): 145156. doi:10.3238/arztebl.m2021.0353.
37. [△]Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? *Immunol Today.* 1993; 14: 353-356.

38. ^ΔRaj Raghupathy, Majedah Al-Azemi, Fawaz Azizieh. Intrauterine growth restriction: cytokine profiles of trophoblast antigen-stimulated maternal lymphocytes. *Clin Dev Immunol*. 2012;2012:734865. doi:10.1155/2012/734865. Epub 2011 Oct 31.
39. ^ΔRaghupathy R. Th1-type immunity is incompatible with successful pregnancy. *Immunol Today*. 1997; 18: 478–482.
40. ^ΔVesce F, Farina A, Jorizzo G, Tarabbia C, Calabrese O, Pelizzola D, Giovannini G, Piffanelli A. Raised level of amniotic endothelin in pregnancies with fetal aneuploidy. *Fetal Diagn Ther*. 1996 Mar-Apr;11(2):94–.
41. ^ΔVesce F, Scapoli C, Giovannini G, Piffanelli A, Geurts-Moespot A, Sweep FC. Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies. *Obstet Gynecol*. 2001 Mar;97(3):404–8.
42. ^ΔBromage SJ, Lang AK, Atkinson I, Searle RF. Abnormal TGFβ levels in the amniotic fluid of Down syndrome pregnancies. *Am J Reprod Immunol*. 2000; 44: 205–210. doi:10.1111/j.8755-8920.2000.440403.x.
43. ^ΔWright A, Zhou Y, Weier JE, Caceres E, Kapidzic M, Tabata T, Kahn M, Nash C, Fisher SJ. Trisomy 21 is associated with variable defects in cytotrophoblast differentiation along the invasive pathway. *Am J Med Genet*. 2004; 130: 354–364. doi:10.1002/ajmg.a.30254.
44. ^ΔVesce F, Scapoli C, Giovannini G, Tralli L, Gotti G, Valerio A, Piffanelli A. Cytokine imbalance in pregnancies with fetal chromosomal abnormalities. *Hum Reprod*. 2002 Mar;17(3):803–8.
45. ^ΔGessi S, Merighi S, Stefanelli A, Mirandola P, Bonfatti A, Fini S, Sensi A, Marci R, Varani K, Borea PA, Vesce F. Downregulation of A (1) and A (2B) adenosine receptors in human trisomy 21 mesenchymal cells from first-trimester chorionic villi. *Biochim Biophys Acta*. 2012 Nov;1822(11):1660–70.
46. ^ΔQinlan Li, Shuting Chen, Xinyi Dong, Sen Fu, Tianyu Zhang, Weiwei Zheng, Yonghong Tian, Donghui Huang. The Progress of Research on Genetic Factors of Recurrent Pregnancy Loss. *Genetic Research*. 2023. doi:10.1155/2023/9164374.
47. ^ΔX Shi, X Xie, Y Jia, S Li. Maternal genetic polymorphisms and unexplained recurrent miscarriage: a systematic review and meta-analysis. *Clin Genet*. 2017; 91(2):265–284. doi:10.1111/cge.12910.
48. ^ΔEngel SA, Erichsen HC, Savitz DA, Thorp J, Chahock S J, Olshan AF. Risk of spontaneous preterm birth is associated with common proinflammatory cytokine polymorphisms. *Epidemiology*. 2005; 16(4):469–77. doi:10.1097/01.ede00016439.09250.31.
49. ^ΔDaniela Holst, Yves Garnier. Preterm birth and inflammation-The role of genetic polymorphisms. *Eur J Obst et Gynecol Reprod Biol*. 2008 Nov;141(1):3–9. doi:10.1016/j.ejogrb.2008.07.020. Epub 2008 Sep 9.
50. ^ΔAnnells MF, Hart PH, Mullighan CG, Heatley SL, Robinson JS, McDonld H. Polymorphisms in immunoregulatory genes and the risk of histologic chorioamnionitis in Caucassoid women: a case control study. *BMC Pregnancy Childbirth*. 2005; 5:4. doi:10.1186/1471-2993-5-4.
51. ^ΔRaghupathy R. Pregnancy: success and failure within the Th1/Th2/Th3 paradigm. *Semin Immunol*. 2001 Aug;13(4):219–27. doi:10.1006/smim.2001.0316. PMID 11437629.
52. ^ΔSchindler AE (January 2004). "First trimester endocrinology: consequences for diagnosis and treatment of pregnancy failure". *Gynecological Endocrinology*. 18 (1): 51–57. doi:10.1080/09513590310001651795. PMID 15106366.
53. ^ΔUlrich U, Pfeifer T, Lauritzen C (September 1994). "Rapid increase in lumbar spine bone density in osteopenic women by high-dose intramuscular estrogen-progestogen injections. A preliminary report". *Hormone and Metabolic Research*. 26 (9): 428–431. doi:10.1055/s-2007-1001723. PMID 7835827. S2CID 260169203.
54. ^ΔUlrich U, Pfeifer T, Buck G, Keckstein J, Lauritzen C (1995). "High-dose estrogen-progestogen injections in gonadal dysgenesis, ovarian hypoplasia, and androgen insensitivity syndrome: Impact on bone density". *Adolescent and Pediatric Gynecology*. 8 (1): 20–23. doi:10.1016/S0932-8610(12)80156-3. ISSN 0932-8610.
55. ^ΔGöretzlehner G, Lauritzen C, Römer T, Rossmanith W (1 January 2012). *Hormontherapien bei gynäkologischen Erkrankungen. Praktische Hormontherapie in der Gynäkologie*. Walter de Gruyter. pp. 227–228. ISBN 978-3-11-024568-4.
56. ^ΔToppozada MK (1983). "Monthly Injectable Contraceptives". In Goldsmith A, Toppozada M (eds.). *Long-Acting Contraception*. pp. 93–103. OCLC 35018604.
57. ^ΔGhadeer AbdulHussain, Fawaz Azizieh, Ma'asoumah Makhseed, Raj Raghupathy. Effects of Progesterone, Dihydroprogesterone and Estrogen on the Production of Th1/Th2/Th17 Cytokines by Lymphocytes from Women with Recurrent Spontaneous Miscarriage. *Reprod Immunol*. 2020 Aug;140: 103132. doi:10.1016/j.jri.2020.103132.
58. ^ΔHassan Shehata, Abdullatif Elfituri, Stergios K. Doumouchtsis, Mudiaga Eseajeberuo Zini, Amanda Ali, Haidar Jan, Ramesh Ganapathy, Hema Divakar, Moshe Hodd. FIGO Good Practice Recommendations on the use of progesterone in the management of recurrent first-trimester miscarriage. *International Journal of Gynecology & Obstetrics*. 2023. doi:10.1002/ijgo.14717.
59. ^ΔAdam J Devall, Argyro Papadopoulou, Marcelina Podeseck, David M Haas, Malcolm J Price, Arri Coomaras

- my, Ioannis D Gallos. Progesterone for preventing miscarriage: a network meta-analysis. *Cochrane Database Syst Rev*. 2021 Apr 19;4(4):CD013792. doi:10.1002/14651858.CD013792.pub2.
60. ^ΔMcLindon LA, James G, Beckmann MM, et al. Progesterone for women with threatened miscarriage (STOP trial): A placebo-controlled randomized clinical trial. *Hum Reprod*. 2023;38(4):560–68. doi:10.1093/humrep/dead029.
61. ^ΔTing-Jung Lai, Sen-Wen Teng, Cheng-Kun Chang, Chen-Yu Huang. "Progesterone in Pregnancy: Evidence-Based Strategies to Reduce Miscarriage and Enhance Assisted Reproductive Technology." *Med Sci Monit*. 2024 Mar 8;30:e943400. doi:10.12659/MSM.943400.
62. ^ΔAdam J Devall, Argyro Papadopoulou, Marcelina Podeseck, David M Haas, Malcolm J Price, Arri Coomarasamy, Ioannis D Gallos. "Progesterone for preventing miscarriage: a network meta-analysis." *Cochrane Database Syst Rev*. 2021 Apr 19;4(4):CD013792. doi:10.1002/14651858.CD013792.pub2.
63. ^ΔArri Coomarasamy, Helen Williams, Ewa Truchanowicz, Paul T Seed, Rachel Small, Siobhan Quenby, Pratima Gupta, Feroza Dawood, Yvonne E M Koot, Ruth Bender Atik, Kitty W M Bloemenkamp, Rebecca Brady, Annette L Briley, Rebecca Cavallaro, Ying C Cheong, Justin J Chu, Abey Eapen, Ayman Ewies, Annemieke Hoek, Eugenie M Kaaijk, Carolien A M Koks, Tin-Chiu Li, Marjory MacLean, Ben W Mol, Judith Moore, Jackie A Ross, Lisa Sharpe, Jane Stewart, Nirmala Vaithilingam, Roy G Farquharson, Mark D Kilby, Yacoub Khalaf, Mariette Goddijn, Lesley Regan, Rajendra Rai. "A Randomized Trial of Progesterone in Women with Recurrent Miscarriages." *N Engl J Med*. 2015 Nov 26;373(22):2141–8. doi:10.1056/NEJMoa1504927.
64. ^ΔW Colin Duncan. "Did the NICE guideline for progesterone treatment of threatened miscarriage get it right?" *Reprod Fertil*. 2022 Apr 7;3(2):C4–C6. doi:10.1530/RAF-21-0122.
65. ^ΔConde-Agudelo A, Romero R. "Vaginal progesterone does not prevent recurrent preterm birth in women with a singleton gestation, a history of spontaneous preterm birth, and a midtrimester cervical length >25 mm." *Am J Obstet Gynecol*. 2022;227:923–6. doi:10.1016/j.ajog.2022.07.054.
66. ^ΔU.S. Food and Drug Administration. "FDA Commissioner and Chief Scientist announce decision to withdraw approval of Makena." FDA; 2023. Accessed April 6, 2023. Available at: <https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena>.
67. ^ΔPrediction and prevention of spontaneous preterm birth. ACOG Practice Bulletin No. 234. American College of Obstetricians and Gynecologists. *Obstet Gynecol*. 2021;138:e65–90. doi:10.1097/AOG.0000000000004479.
68. ^ΔAnne-Marie Aubin, Liam McAuliffe, Kimberley Williams, Ashad Issah, Rosanna Diacci, Jack E McAuliffe, Salma Sabdia, Jason Phung, Carol A Wang, Craig E Penneil. "Combined vaginal progesterone and cervical cerclage in the prevention of preterm birth: a systematic review and meta-analysis." *Am J Obstet Gynecol MFM*. 2023 Aug;5(8):101024. doi:10.1016/j.ajogmf.2023.101024. Epub 2023 May 20.
69. ^ΔFrancesco D'Antonio, Vincenzo Berghella, Daniele Di Mascio, Gabriele Saccone, Filomena Sileo, Maria Elena Flacco, Anthony O Odibo, Marco Liberati, Lamberto Manzoli, Asma Khalil. "Role of progesterone, cerclage and pessary in preventing preterm birth in twin pregnancies: A systematic review and network meta-analysis." *Eur J Obstet Gynecol Reprod Biol*. 2021 Jun;261:166–177. doi:10.1016/j.ejogrb.2021.04.023. Epub 2021 Apr 24.
70. ^ΔDennis W. Thomas, Paulo N. Rocha, Chandra Nataraj, Lisa A. Robinson, Robert F. Spurney, Beverly H. Koller, Thomas M. Coffman. "Proinflammatory Actions of Thromboxane Receptors to Enhance Cellular Immune Responses." *J Immunol*. 2003;171(12):6389–6395. doi:10.4049/jimmunol.171.12.6389.
71. ^ΔM Tulppala, M Marttunen, V Söderstrom-Anttila, T Foudila, K Ailus, T Palosuo, O Ylikorkala. "Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production." *Hum Reprod*. 1997 Jul;12(7):1567–72. doi:10.1093/humrep/12.7.1567.
72. ^ΔS W Walsh. "Low-dose aspirin: treatment for the imbalance of increased thromboxane and decreased prostacyclin in preeclampsia." *Am J Perinatol*. 1989 Apr;6(2):124–32. doi:10.1055/s-2007-999562.
73. ^ΔAmerican College of Obstetricians and Gynecologists. "Hypertension in pregnancy." Washington, DC: American College of Obstetricians and Gynecologists; 2013. Available at: <http://www.acog.org/Resources-And-Publications/Task-Force-and-Work-Group-Reports/Hypertension-in-Pregnancy>. Retrieved January 24, 2018.
74. ^ΔPaulien G de Jong, Stef Kaandorp, Marcello Di Nisio, Mariëtte Goddijn, Saskia Middeldorp. "Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia." *Cochrane Database Syst Rev*. 2014 Jul 4;2014(7):CD004734. doi:10.1002/14651858.CD004734.pub4.
75. ^ΔHalide Yuksel, Semra Kayatas, Aysen Telce Boza, Murat Api, A Aktug Ertekin, Cetin Cam. "Low molecular w

- eight heparin use in unexplained recurrent miscarriage." *Pak J Med Sci*. 2014 Nov-Dec;30(6):1232–1237. doi:10.12669/pjms.306.5477.
76. [△]Hamulyák EN, Scheres LJJ, Marijnen MC, Goddijn M, Middeldorp S. "Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss." *Cochrane Database of Systematic Reviews*. 2020, Issue 5. Art. No.: CD012852. doi:10.1002/14651858.CD012852.pub2.
 77. [△]Siobhan Quenby, Katie Booth, Louise Hiller, Arri Coomarasamy, Paulien G de Jong, Eva N Hamulyák, Luuk J Scheres, Thijs F van Haaps, Lauren Ewington, Shreeya Tewary, Mariëtte Goddijn, Saskia Middeldorp; ALIFE 2 Block Writing Committee; ALIFE2 Investigators. "Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial." *Lancet*. 2023 Jul 1;402(10395):54–61. doi:10.1016/S0140-6736(23)00693-1. Epub 2023 Jun 1.
 78. [△]Drugs and pregnancy. Edited by D. F. Hawkins. Second Edition. ChurchillLivingstone 1987, pag 85; pag 219
 79. [△]Anthony E Michael, Aris T Papageorgiou. "Potential significance of physiological and pharmacological glucocorticoids in early pregnancy." *Hum Reprod Update*. 2008 Sep-Oct;14(5):497–517. doi:10.1093/humupd/dmn021. Epub 2008 Jun 13.
 80. [△]Fantuzzi G, Ghezzi P. "Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory disease." *Mediators Inflamm*. 1993;2(4):263–70. doi:10.1155/S0962935193000365.
 81. [△]Gottschall PE, Koves K, Mizuno K, Tatsuno I, Arimura A. "Glucocorticoid upregulation on interleukin-1 receptor expression in a glioblastoma cell line." *Am J Physiol*. 1991 Sep;261(3Pt1):E362–8. doi:10.1152/ajpendo.1991.261:E362-E368.
 82. [△]Chinenov Y, Rogatsky I. "Glucocorticoids and the innate immune system: crosstalk with the toll-like receptor or signalling network." *Mol Cell Endocrinol*. 2007 Sep 15;275(1–2):30–42. doi:10.1016/j.mce.2007.04.014. Epub 2007 May 13.
 83. [△]Broering R, Montag M, Jiang M, Lu M, Sowa JP, Kleinherr K, Gerken G, Schlaak JF. "Corticosteroids shift the Toll-Like receptor response pattern of primary isolated murine liver cells from an inflammatory to an anti-inflammatory state." *Int Immunol*. 2011 Sep;23(9):537–44. doi:10.1093/intimm/dxr048. Epub 2011 Jul 1.
 84. [△]Christopher D. Clark, Donna A. Santillan, Mark K. Santillan. "Betamethasone reverses AVP-induced dysfunction in trophoblast cells." POSTER SESSION III | FRIDAY, FEBRUARY 4, 2022 • 10:30 AM – 12:00 PM Volume 226, Issue 1, Supplement S443–S444 January 2022.
 85. [△]F Vesce, M C Pareschi, S Travagli, C Tarabbia, F Pansini, G Salvatorelli, A M Gulinati, E Grandi, C Biondi. "Betamethasone-induced lecithin release in vitro from the fetal membranes." *Gynecol Obstet Invest*. 1992;33(3):134–7. doi:10.1159/000294866.
 86. [△]Yong-Sung Choi, Chae-Young Kim, Hye Kyung Chang, Young Joo Lee, Sung-Hoon Chung. "Antenatal Betamethasone Induces Increased Surfactant Proteins and Decreased Foxm1 Expressions in Fetal Rabbit Pups." *Int J Med Sci*. 2021 Jul 25;18(15):3367–3372. doi:10.7150/ijms.62286.
 87. [△]E. Murphy, R.J. Fittock, P.K. Zarzycki, M.M. Delahunty, R. Smith, V.L. Clifton. "Metabolism of Synthetic Steroids by the Human Placenta." *Placenta*. Volume 28, Issue 1, January 2007, Pages 39–46. doi:10.1016/j.placenta.2005.12.010.
 88. [△]N Costedoat-Chalumeau, S Georgin-Lavialle, Z Amoura, J C Piette. "Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block." *Lupus*. 2005;14(9):660–4. doi:10.1191/0961203305lu2195oa.
 89. [△]K Shinohara, S Miyagawa, T Fujita, T Aono, K Kidoguchi. "Neonatal lupus erythematosus: results of maternal corticosteroid therapy." *Obstet Gynecol*. 1999 Jun;93(6):952–7. doi:10.1016/S0029-7844(99)00006-X.
 90. [△]A J J T Rein, D Mevorach, Z Perles, S Gavri, M Nadjari, A Nir, U Elchalal. "Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study." *Circulation*. 2009 Apr 14;119(14):1867–72. doi:10.1161/CIRCULATIONAHA.108.773143. Epub 2009 Mar 30.
 91. [△]Mevorach D, Elchalal U, Rein AJJT. Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block. *Curr Opin Rheumatol*. 2009 Sep;21(5):478–82. doi:10.1097/BO.R.0b013e32832ed817.
 92. [△]Hayashi T, Kaneko M, Kim KS, Eryu Y, Shindo T, Isoda T, Murashima A, Ito Y, Sago H. Outcome of prenatally diagnosed isolated congenital complete atrioventricular block treated with transplacental betamethasone or ritodrine therapy. *Pediatr Cardiol*. 2009 Jan;30(1):35–40. doi:10.1007/s00246-008-9273-5. Epub 2008 Jul 26.
 93. [△]Brucato A. Prevention of congenital heart block in children of SSA-positive mothers. *Rheumatology*. 2008 Jun;47(suppl_3):iii35–iii37. doi:10.1093/rheumatology/ken153.
 94. [△]Wada YS, Hama I, Goto M, Ito Y, Murashima. Long-term physical and neurodevelopmental outcomes after

- antenatal betamethasone administration for congenital heart block prevention. *J Matern Fetal Neonatal Med*. 2022 Nov;35(21):4175–4178. doi:10.1080/14767058.2020.1849089. PMID 33207991.
95. ^ΔSpeiser PW, White PC. Congenital adrenal hyperplasia. *N Engl J Med*. 2003 Aug 21;349(8):776–88. doi:10.1056/NEJMra021561.
 96. ^ΔNimkarn S, New MI. Steroid 11beta-hydroxylase deficiency congenital adrenal hyperplasia. *Trends Endocrinol Metab*. 2008 Apr;19(3):96–9. doi:10.1016/j.tem.2008.01.002. Epub 2008 Feb 21.
 97. ^ΔCarlson AD, Obeid JS, Kanellopoulou N, Wilson RC, New MI. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. *J Steroid Biochem Mol Biol*. 1999 Apr-Jun;69(1-6):19–29. doi:10.1016/s0960-0760(99)00059-x.
 98. ^ΔNew MI, Tong YK, Yuen T, Jiang P, Pina C, Chan KCA, Khattab A, Liao GJW, Yau M, Kim SM, Chiu RWK, Sun L, Zaidi M, Lo YMD. Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia Using Cell-Free Fetal DNA in Maternal Plasma. *J Clin Endocrinol Metab*. 2014 Feb 28;99(6):E1022–E1030. doi:10.1210/jc.2014-1118.
 99. ^ΔPeranteau WH, Wilson RD, Liechty KW, Johnson MP, Bebbington MW, Hedrick HL, Flake AW, Adzick NS. Effect of maternal betamethasone administration on prenatal congenital cystic adenomatoid malformation growth and fetal survival. *Fetal Diagn Ther*. 2007;22(5):365–71. doi:10.1159/000103298. Epub 2007 Jun 5.
 100. ^ΔLeung WC, Ngai C, Lam TPW, Chan KL, Lao TT, Tang MHY. Unexpected intrauterine death following resolution of hydrops fetalis after betamethasone treatment in a fetus with a large cystic adenomatoid malformation of the lung. *Ultrasound Obstet Gynecol*. 2005 Jun;25(6):610–2. doi:10.1002/uoq.1912.
 101. ^ΔYamashita A, Hidaka N, Yamamoto R, Nakayama S, Sasahara J, Ishii K, Mitsuda N. In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review. *J Clin Ultrasound*. 2015 Sep;43(7):451–7. doi:10.1002/jcu.22214. Epub 2014 Jul 15.
 102. ^ΔMurphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. *Br J Haematol*. 2007 Feb;136(3):366–78. doi:10.1111/j.1365-2141.2006.06418.x.
 103. ^ΔArnold DM, Smith JW, Kelton JG. Diagnosis and management of neonatal alloimmune thrombocytopenia. *Transfus Med Rev*. 2008 Oct;22(4):255–67. doi:10.1016/j.tmr.2008.05.003.
 104. ^ΔD'Ippolito S, Gavi F, Granieri C, De Waure C, et al. (2025). Efficacy of corticosteroids in patients with recurrent pregnancy loss: A systematic review and meta-analysis. *Am J Reprod Immunol*. 93(1). doi:10.1111/aji.70037.
 105. ^ΔDosiou C, Giudice LC. Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. *Endocr Rev*. 2005 Feb;26(1):44–62. doi:10.1210/er.2003-0021.
 106. ^ΔXu B, Makris A, Thomson C, Hennessy A. Glucocorticoids inhibit placental cytokines from cultured normal and preeclamptic placental explants. *Placenta*. 2005;26:654–60.
 107. ^ΔQuenby S, Farquharson R, Young M, Vince G. Successful pregnancy outcome following 19 consecutive miscarriages: case report. *Hum Reprod*. 2003 Dec;18(12):2562–4. doi:10.1093/humrep/deg502.
 108. ^ΔHenderson TA, Saunders PTK, Moffett-King A, Groom NP, Critchley HOD. Steroid Receptor Expression in Uterine Natural Killer Cells. *The Journal of Clinical Endocrinology & Metabolism*. 2003 Jan;88(1):440–449. doi:10.1210/jc.2002-021174.
 109. ^ΔTempfer CB, Kurz C, Bentz EK, Unfried G, Walch K, Cizek U, Huber JC. A combination treatment of prednisone, aspirin, folate, and progesterone in women with idiopathic recurrent miscarriage: a matched-pair study. *Fertil Steril*. 2006 Jul;86(1):145–8. doi:10.1016/j.fertnstert.2005.12.035. Epub 2006 May 23.
 110. ^ΔSandman CA, Glynn L, Dunkel Schetter C, Wadhwa P, Garite T, Chicz-DeMet A, Hobel C. Elevated maternal cortisol early in pregnancy predicts third trimester levels of placental corticotropin releasing hormone (CRH): priming the placental clock. *Peptides*. 2006 Jun;27(6):1457–63. doi:10.1016/j.peptides.2005.10.002. Epub 2005 Nov 22.
 111. ^ΔLunghi L, Pavan B, Biondi C, Paolillo R, Valerio A, Vesce F, Patella A. Use of glucocorticoids in pregnancy. *Curr Pharm Des*. 2010;16(32):3616–37. doi:10.2174/138161210793797898.
 112. ^ΔVesce F, Giugliano E, Cagnazzo E, Bignardi S, Mossuto E, Servello T, Marci R. The role of glucocorticoids in pregnancy: four decades experience with use of betamethasone in the prevention of pregnancy loss. In “Glucocorticoids. New recognition of our familiar friend”. Edited by Xiaoxiao Qian, INTECH, November 2012, Croatia, pag 407–48. doi:10.5772/50797.
 113. ^ΔVesce F, Giugliano E, Cagnazzo E, Mossuto E, Marci R. Low dose of betamethasone throughout the whole course of pregnancy and fetal growth: a clinical study. *Eur Rev Med Pharmacol Sci*. 2014;18(4):593–8.

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.